| Application: | 52217, Serum cardiometabolic biomarkers in relation to all-cause and cause-specific mortality |
| Title: | Pre-diagnostic circulating concentrations of insulin-like growth factor-1 and risk of COVID-19 mortality: results from UK Biobank |
| Size: | 596154 B |
| Archived: | 6 Aug 2021 |
| Stability: | Complete |
| Personal: | No individual-level data |
Return 3736
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Notes
Coronavirus disease 2019 (COVID-19) deteriorates suddenly primarily due to excessive inflammatory injury, and insulin-like growth factor-1 (IGF-1) is implicated in endocrine control of the immune system. However, the effect of IGF-1 levels on COVID-19 prognosis remains unknown. Using UK Biobank resource, we investigated the association between circulating IGF-1 concentrations and mortality risk (available death data updated on 07 Sep 2020) among COVID-19 patients who had pre-diagnostic serum IGF-1 measurements at baseline (2006-2010). Unconditional logistic regression was performed to estimate the odds ratio (OR) and 95% confidence intervals (CIs) of mortality. Among 1670 COVID-19 patients, 415 deaths occurred due to COVID-19. Compared to the lowest quartile of IGF-1 concentrations, the highest quartile was associated with a 41% lower risk of mortality (OR = 0.59, 95% CI 0.41-0.86, P-trend = 0.01). In the continuous model, per 1-standard deviation increment in log-transformed IGF-1 was associated with a 15% reduction in the risk (intraclass correlation coefficients corrected OR = 0.85, 95% CI 0.73-0.99). The association was largely consistent in the various stratified and sensitivity analyses. In conclusion, our data suggest that higher IGF-1 concentrations are associated with a lower risk of COVID-19 mortality. Further studies are required to determine whether and how targeting IGF-1 pathway might improve COVID-19 prognosis.Application 52217
Serum cardiometabolic biomarkers in relation to all-cause and cause-specific mortality
Despite substantial epidemiologic evidence supports the association between cardiometabolic biomarkers and risk of cardiovascular, metabolic disease and cancer, how these biomarkers may influence all-cause and cause-specific mortality remain to be established. Previous studies were limited by the relatively small sample size, inclusion of men or women only, short duration of follow up, examination of CVD or cancer mortality only, or inadequate control for confounding. Therefore, a systematic investigation of cardiometabolic biomarkers with mortality in a large-scale cohort is needed to better understand the role of metabolic disturbances in death risk. We will utilize data from UK biobank to prospectively investigate associations of 14 serum biomarkers, including lipid profiles (i.e., Cholesterol, Direct Low Density Lipoprotein, HDL-Cholesterol, Triglyceride, Apolipoprotein A, and Lipoprotein (a)), inflammatory marker (C-reactive Protein), IGF1, HbA1c, glucose, and sex hormones (i.e., testosterone, oestradiol, sex hormone binding globulin), with the risk of all-cause and cause-specific mortality (i.e., death from CVD, cancer, and other causes).
| Lead investigator: | Dr Dong Hang |
| Lead institution: | Nanjing Medical University |
1 related Return
| Return ID | App ID | Description | Archive Date |
|---|---|---|---|
| 3735 | 52217 | Vitamin D Status and Risk of All-Cause and Cause-Specific Mortality in a Large Cohort: Results From the UK Biobank | 6 Aug 2021 |
1 Publication
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 3737 | Pre-diagnostic circulating concentrations of insulin-like growth factor-1 and risk of COVID-19 mortality: results from UK Biobank | Xikang Fan (+9) | 2021 | European Journal of Epidemiology |
Enabling scientific discoveries that improve human health